跳至主要内容
临床试验/NCT03268902
NCT03268902已完成2 期

Early Life Interventions for Childhood Growth and Development In Tanzania

Haydom Lutheran Hospital1 个研究点 分布在 1 个国家目标入组 1,188 人开始时间: 2017年9月5日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
1,188
试验地点
1
主要终点
Height-for-age z-score (HAZ) at 18 months

研究概览

简要总结

This study aims to assess growth and cognitive effects of treatment with azithromycin and nitazoxanide and/or nicotinamide (vitamin B3) supplementation nicotinamide.

详细描述

Children living in rural sub-Saharan Africa experience massive challenges to child thriving, with poor linear growth and delays in child development. In a cohort of 211 children living in the rural Haydom area of Tanzania (participating in the Interactions of Malnutrition & Enteric Infections: Consequences for Child Health and Development "MAL-ED" Study), 70.6% had stunted growth at 18 months. This rate of moderate and severe stunting (length-for-age z-score [HAZ] <-2 standard deviations) was the highest of the 8 study sites in MAL-ED.

This enormous deficit is likely associated with high rates of enteric infections with Campylobacter, E. coli pathotypes, Cryptosporidium, and Giardia, organisms susceptible to azithromycin and/or nitazoxanide. Infections such as these occur frequently in developing areas and are often associated with environmental enteropathy, including ongoing enteric inflammation and loss of enterocyte integrity, leading to possible bacterial translocation and poorer absorption of ingested nutrients. The consequences of these infections, enteric dysfunction and poor nutrient absorption frequently include growth stunting, learning delays, and an overall loss of human capital.

Emerging evidence suggests a potential role for the tryptophan-niacin pathway (including the end-product nicotinamide, an isoform of vitamin B3) in decreasing mucosal inflammation and affecting enteral microbiota. At the Tanzania site of MAL-ED, serum levels of tryptophan were related to subsequent linear growth, further suggesting importance of the tryptophan-niacin pathway. What is not clear is whether early childhood growth and development could be improved by targeting enteric infection and the tryptophan-niacin pathway by 1) delivering antibiotics against specific bacteria and/or 2) providing vitamin B3 as nicotinamide/niacinamide.

The main analysis will be intention-to-treat but a secondary analysis will be per protocol.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Both participants and investigators will be blinded to the treatments allocated to each participant. The members of the DSMB will also be blinded.

入排标准

年龄范围
0 Days 至 14 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Maternal age ≥18
  • Infant ≤ 14 days

排除标准

  • Maternal inability to adhere to protocol
  • Multiple gestation
  • Severe illness (significant birth defect, hospitalization, severe neonatal illness)
  • Birth weight <1500 g
  • Lack of breastfeeding at enrollment (and lack of intention to continue breastfeeding at time of enrollment).

研究组 & 干预措施

Nicotinamide and Antimicrobials

Experimental

Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension

干预措施: Azithromycin Oral Liquid Product (Drug)

Nicotinamide and Antimicrobials

Experimental

Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension

干预措施: Nitazoxanide Oral Suspension (Drug)

Nicotinamide and Antimicrobials

Experimental

Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension

干预措施: Nicotinamide (Dietary Supplement)

Antimicrobials only

Experimental

Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension

干预措施: Azithromycin Oral Liquid Product (Drug)

Antimicrobials only

Experimental

Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension

干预措施: Nitazoxanide Oral Suspension (Drug)

Antimicrobials only

Experimental

Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension

干预措施: Placebos (Drug)

Nicotinamide only

Experimental

Nicotinamide Placebo Placebo

干预措施: Nicotinamide (Dietary Supplement)

Nicotinamide only

Experimental

Nicotinamide Placebo Placebo

干预措施: Placebos (Drug)

No active treatment

Placebo Comparator

Placebo Placebo Placebo

干预措施: Placebos (Drug)

结局指标

主要结局

Height-for-age z-score (HAZ) at 18 months

时间窗: 18 months

次要结局

  • Stunting(18 months)
  • All cause mortality(0-18 months)
  • Weight-for-age z-score (WAZ) at 18 months(18 months)
  • Head circumference-for-age z-score (HCAZ) at 18 months(18 months)
  • Hospitalization(0-18 months)
  • Childhood illness(0-18 months)
  • Anemia(12 and 18 months)
  • Enteropathogen burden(6, 6.5, 12, 12.5, 18 months)
  • Microbiota composition(6, 6.5, 12, 18 months)
  • Stool myeloperoxidase concentration(6, 12, 18 months)
  • C-reactive protein concentration in serum(12 and 18 months)
  • Insulin-like growth factor 1 concentration in serum(12 and 18 months)
  • Collagen X concentration in serum(12 and 18 months)
  • Tryptophan-kynurenine ratio(12 and 18 months)
  • Niacin and nicotinamide metabolite concentration(6, 12, 18 months)
  • Small intestinal bacterial overgrowth(6, 12 and 18 months)
  • Malawi Developmental Assessment Tool score(18 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验